These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 23442582)

  • 1. Positive Phase 1 interim results for killed whole-virus HIV vaccine.
    Riedmann EM
    Hum Vaccin Immunother; 2013 Jan; 9(1):7. PubMed ID: 23442582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses.
    Choi E; Michalski CJ; Choo SH; Kim GN; Banasikowska E; Lee S; Wu K; An HY; Mills A; Schneider S; Bredeek UF; Coulston DR; Ding S; Finzi A; Tian M; Klein K; Arts EJ; Mann JF; Gao Y; Kang CY
    Retrovirology; 2016 Nov; 13(1):82. PubMed ID: 27894306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salk group testing killed-virus AIDS vaccine.
    Minn Med; 1994 Jul; 77(7):55. PubMed ID: 8052210
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).
    García F; Bernaldo de Quirós JC; Gómez CE; Perdiguero B; Nájera JL; Jiménez V; García-Arriaza J; Guardo AC; Pérez I; Díaz-Brito V; Conde MS; González N; Alvarez A; Alcamí J; Jiménez JL; Pich J; Arnaiz JA; Maleno MJ; León A; Muñoz-Fernández MA; Liljeström P; Weber J; Pantaleo G; Gatell JM; Plana M; Esteban M
    Vaccine; 2011 Oct; 29(46):8309-16. PubMed ID: 21907749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial.
    Viegas EO; Tembe N; Nilsson C; Meggi B; Maueia C; Augusto O; Stout R; Scarlatti G; Ferrari G; Earl PL; Wahren B; Andersson S; Robb ML; Osman N; Biberfeld G; Jani I; Sandström E
    AIDS Res Hum Retroviruses; 2018 Feb; 34(2):193-205. PubMed ID: 28969431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of placebos in Phase 1 preventive HIV vaccine clinical trials.
    Huang Y; Karuna ST; Janes H; Frahm N; Nason M; Edlefsen PT; Kublin JG; Corey L; McElrath MJ; Gilbert PB
    Vaccine; 2015 Feb; 33(6):749-52. PubMed ID: 25454855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection.
    Hemachandra A; Puls RL; Sirivichayakul S; Kerr S; Thantiworasit P; Ubolyam S; Cooper DA; Emery S; Phanuphak P; Kelleher A; Ruxrungtham K
    Hum Vaccin; 2010 Oct; 6(10):835-40. PubMed ID: 20864808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy of HIV-seropositive patients: preliminary report on a dose-ranging study.
    Slade H; Turner J; Abrams C; Carlo D; Salk J
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1329-31. PubMed ID: 1361349
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.
    Hayes P; Gilmour J; von Lieven A; Gill D; Clark L; Kopycinski J; Cheeseman H; Chung A; Alter G; Dally L; Zachariah D; Lombardo A; Ackland J; Sayeed E; Jackson A; Boffito M; Gazzard B; Fast PE; Cox JH; Laufer D
    Clin Vaccine Immunol; 2013 Mar; 20(3):397-408. PubMed ID: 23345581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV vaccine fails in phase 3 trial.
    McCarthy M
    Lancet; 2003 Mar; 361(9359):755-6. PubMed ID: 12620743
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial.
    Boffito M; Fox J; Bowman C; Fisher M; Orkin C; Wilkins E; Jackson A; Pleguezuelos O; Robinson S; Stoloff GA; Caparrós-Wanderley W
    Vaccine; 2013 Nov; 31(48):5680-6. PubMed ID: 24120550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate.
    Bellino S; Francavilla V; Longo O; Tripiciano A; Paniccia G; Arancio A; Fiorelli V; Scoglio A; Collacchi B; Campagna M; Lazzarin A; Tambussi G; Din CT; Visintini R; Narciso P; Antinori A; D'Offizi G; Giulianelli M; Carta M; Di Carlo A; Palamara G; Giuliani M; Laguardia ME; Monini P; Magnani M; Ensoli F; Ensoli B
    Rev Recent Clin Trials; 2009 Sep; 4(3):195-204. PubMed ID: 20028332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, placebo-controlled, blind anti-AIDS clinical trial: safety and immunogenicity of a specific anti-IFN alpha immunization.
    Gringeri A; Santagostino E; Mannucci PM; Tradati F; Cultraro D; Buzzi A; Criscuolo M; David A; Guillemot L; Barré-Sinoussi F
    J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):978-88. PubMed ID: 7914235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137).
    Valentine FT; Kundu S; Haslett PA; Katzenstein D; Beckett L; Spino C; Borucki M; Vasquez M; Smith G; Korvick J; Kagan J; Merigan TC
    J Infect Dis; 1996 Jun; 173(6):1336-46. PubMed ID: 8648205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials.
    Gilbert PB; Chiu YL; Allen M; Lawrence DN; Chapdu C; Israel H; Holman D; Keefer MC; Wolff M; Frey SE;
    Vaccine; 2003 Jun; 21(21-22):2933-47. PubMed ID: 12798637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.
    Baden LR; Walsh SR; Seaman MS; Cohen YZ; Johnson JA; Licona JH; Filter RD; Kleinjan JA; Gothing JA; Jennings J; Peter L; Nkolola J; Abbink P; Borducchi EN; Kirilova M; Stephenson KE; Pegu P; Eller MA; Trinh HV; Rao M; Ake JA; Sarnecki M; Nijs S; Callewaert K; Schuitemaker H; Hendriks J; Pau MG; Tomaka F; Korber BT; Alter G; Dolin R; Earl PL; Moss B; Michael NL; Robb ML; Barouch DH;
    J Infect Dis; 2018 Jul; 218(4):633-644. PubMed ID: 29669026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group.
    Keefer MC; Wolff M; Gorse GJ; Graham BS; Corey L; Clements-Mann ML; Verani-Ketter N; Erb S; Smith CM; Belshe RB; Wagner LJ; McElrath MJ; Schwartz DH; Fast P
    AIDS Res Hum Retroviruses; 1997 Sep; 13(14):1163-77. PubMed ID: 9310283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events.
    Schmidt C; Smith C; Barin B; Bakhtyari A; Bart PA; Bekker LG; Chomba E; Clumeck N; Ho D; Hoosen A; Jaoko W; Kaleebu P; Karita E; Keefer MC; van Lunzen J; McMichael A; Mehendale S; Peters B; Ramanathan VD; Robinson A; Rockstroh J; Vardas E; Vets E; Weber J; Graham BS; Than S; Excler JL; Kochhar S; Ho M; Heald A; Fast PE
    Hum Vaccin Immunother; 2012 May; 8(5):630-8. PubMed ID: 22634443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.
    Mpendo J; Mutua G; Nyombayire J; Ingabire R; Nanvubya A; Anzala O; Karita E; Hayes P; Kopycinski J; Dally L; Hannaman D; Egan MA; Eldridge JH; Syvertsen K; Lehrman J; Rasmussen B; Gilmour J; Cox JH; Fast PE; Schmidt C
    PLoS One; 2015; 10(8):e0134287. PubMed ID: 26252526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.